Ariad Pharmaceuticals Inc fka ARIA

[BTH]

Hey, I'd be perfectly fine with it.

I, however, just do not see that happening until a few years, or at least, until ARIA was WELL into a Phase 3 head-to-head trial with Sprycel or Tasigna....

In fact, I predict if Ponatinib is successful in PACE, and ARIA eventually has a market-cap over +$2 billion, large pharma, the bumbling idiots that they are, could very well pay $5 billion for the company, years down the line.